• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC HEART VALVES DIVISION EVOLUT FX VALVE; AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIV

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC HEART VALVES DIVISION EVOLUT FX VALVE; AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIV Back to Search Results
Model Number EVOLUTFX-23
Device Problems Difficult to Advance (2920); Device Dislodged or Dislocated (2923); Patient Device Interaction Problem (4001)
Patient Problems Low Blood Pressure/ Hypotension (1914); Cardiac Tamponade (2226); Vascular Dissection (3160); Pericardial Effusion (3271); Heart Block (4444)
Event Date 02/08/2024
Event Type  Injury  
Manufacturer Narrative
Continuation of d10: section d information references the main component of the system.Other relevant device(s) are: product id: e volutfx-23, serial/lot #: (b)(6), ubd: 11-dec-2025, udi#: (b)(4).Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
 
Event Description
Medtronic received information that during implant of this transcatheter bioprosthetic valve, the valve (b)(6) dislodged unnoticed during subclavian treatment and was snared.Per the physician, it appeared that the guidewire was left in place when the pigtail catheter that had been inserted through the lower leg was removed, or that the guidewire got caught and pulled while stuck.An ascending aorta dissection was suspected, however no dissection was visible on computed tomography (ct) scan.The team decided to implant a second valve (b)(6).Subclavian approach was considered too dangerous, therefore the team switched to right transfemoral approach.The second valve (b)(6) was inserted, but the guidewire appeared to stray into the stent frame and did not pass through.The patient's blood pressure decreased while the wire was being crossed again.Pericardial effusion increased, and was punctured due to cardiac tamponade.When the guidewire was inserted, it entered the false lumen and caused a large dissection.The cardiac tamponade was resolved and the valve (b)(6) was placed.There were no problems with placement: the outflow side did not spread, but the paddles came off.  an 18fr introducer sheath was inserted with no problem in order to place viabahn: one viabahn was placed in the right lower limb and one viabahn was placed in the subclavian artery, near the synthetic vascular junction.  following placement of the second valve, the patient had a complete atrio-ventricular (av) block.No additional adverse patient effects were reported.
 
Manufacturer Narrative
This is a system report.The information is for the primary device, which was in use with the following: brand name [evolutfx dcs] product id [d-evolutfx-2329] serial/lot (b)(6) use by date [2025-10-11] udi (b)(4).This is a system report.The information is for the primary device, which was in use with the following: brand name [guidewire] product id [gwbc30] use by date udi additional codes: annex f code f12 was added the codes present in correspond to multiple components/products that comprise this reported event.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
 
Event Description
Additional information was received that clarified previously reported information.Per the physician, the medtronic guidewire got caught and pulled while stuck.The guidewire was stuck because it was left in place after the pigtail catheter had been inserted through the lower leg and was withdrawn.It was further reported that a pre-implant balloon aortic valvuloplasty (bav) was performed.Patient anatomy was not a contributing factor to the dislodgement.The deployment starting point was at the bottom of the pigtail catheter, and the direction of the dislodge was aortic.Prior to valve dislodgement, the implant depth on the non-coronary cusp (ncc) was 3 millimeter¿s (mm) and the implant depth on the left coronary cusp (lcc) was 3 mm.Per the physician, the valve did not cause or contribute to the dissection.Per the physician, the delivery catheter system (dcs) and in-line sheath damaged the subclavian artery because the inline sheath did not pass through the patient¿s anatomy which necessitated for the use of an 18 french sheath.The cause of the dissection was due to smaller vessel diameters.1 day following the implant of the valve, a permanent pacemaker was implanted for complete heart block (chb).No additional adverse patient effects were reported.
 
Event Description
Additional information was received that during the valve procedure, two dissections occurred with the first delivery catheter system (dcs) used.The location of the dissection's were the subclavian artery and the femoral artery.
 
Manufacturer Narrative
This event has been identified as a duplicate to regulatory report number (b)(4).Please reference (b)(4) for any additional information.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EVOLUT FX VALVE
Type of Device
AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIV
Manufacturer (Section D)
MEDTRONIC HEART VALVES DIVISION
1851 e deere ave
santa ana CA 92705
Manufacturer (Section G)
MEDTRONIC HEART VALVES DIVISION
1851 e deere ave
santa ana CA 92705
Manufacturer Contact
alison sweeney
parkmore business park west
galway 
EI  
091708096
MDR Report Key18736966
MDR Text Key335701202
Report Number2025587-2024-00987
Device Sequence Number1
Product Code NPT
Combination Product (y/n)N
Reporter Country CodeJA
PMA/PMN Number
P130021
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional
Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup,Followup
Report Date 03/26/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received02/20/2024
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Model NumberEVOLUTFX-23
Device Catalogue NumberEVOLUTFX-23
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received03/15/2024
Date Device Manufactured11/14/2023
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Treatment
"SEE H11...."
Patient Outcome(s) Required Intervention; Life Threatening;
-
-